Abstract
Theranostic medicine has become more promising in cancer treatment, where the cancer diagnosis and chemotherapy are combined for early diagnosis and precise treatment with improved efficacy and reduced side effects. Nanotechnology has played a critical role in developing various nanomaterials with engendered smart functions and targeted delivery. The rapid development of structural DNA nanotechnology has enabled the design and fabrication of complex nanostructures with prescribed 1D, 2D and 3D patterns in vitro and in vivo. Self-assembled DNA nanostructures can serve as drug delivery platforms that are integrated with various functions ranging from molecular recognition and computations, dynamically structural switch to carrying molecular payloads and selectively release. In this review, we summarize recent exciting progress of using DNA nanostructures to engineer novel smart drug-delivery systems potential for treating cancer.
Keywords: Cancer theranostics, DNA nanotechnology, Spherical nucleic acids, DNA nanorobot, Smart drug delivery.
Current Topics in Medicinal Chemistry
Title:Self-assembled Nucleic Acid Nanostructures for Cancer Theranostic Medicines
Volume: 17 Issue: 16
Author(s): Jinglin Fu*, Gabriele Stankeviciute, Sung Won Oh, John Collins, Yinghui Zhong and Ting Zhang
Affiliation:
- Center for Computational and Integrative Biology, Department of Chemistry, Rutgers University-Camden, 315 Penn Street, Science Building, Camden, NJ 08102,United States
Keywords: Cancer theranostics, DNA nanotechnology, Spherical nucleic acids, DNA nanorobot, Smart drug delivery.
Abstract: Theranostic medicine has become more promising in cancer treatment, where the cancer diagnosis and chemotherapy are combined for early diagnosis and precise treatment with improved efficacy and reduced side effects. Nanotechnology has played a critical role in developing various nanomaterials with engendered smart functions and targeted delivery. The rapid development of structural DNA nanotechnology has enabled the design and fabrication of complex nanostructures with prescribed 1D, 2D and 3D patterns in vitro and in vivo. Self-assembled DNA nanostructures can serve as drug delivery platforms that are integrated with various functions ranging from molecular recognition and computations, dynamically structural switch to carrying molecular payloads and selectively release. In this review, we summarize recent exciting progress of using DNA nanostructures to engineer novel smart drug-delivery systems potential for treating cancer.
Export Options
About this article
Cite this article as:
Fu Jinglin*, Stankeviciute Gabriele, Oh Won Sung, Collins John, Zhong Yinghui and Zhang Ting, Self-assembled Nucleic Acid Nanostructures for Cancer Theranostic Medicines, Current Topics in Medicinal Chemistry 2017; 17 (16) . https://dx.doi.org/10.2174/1568026617666161122115722
DOI https://dx.doi.org/10.2174/1568026617666161122115722 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Application of Optical Technology in Microfluidic Systems
Current Proteomics Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design The Network of Fibroblastic Reticular Cells in the Lymph Node:Functional Framework for Immune Surveillance
Current Immunology Reviews (Discontinued) Design, Synthesis and Biological Evaluation of 4-(Imidazolylmethyl)-2- Aryl-Quinoline Derivatives as Aromatase Inhibitors and Anti-breast Cancer Agents
Letters in Drug Design & Discovery HSP60 as a Drug Target
Current Pharmaceutical Design Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Gut Inflammation in Response to Injury: Potential Target for Therapeutic Intervention
Recent Patents on Anti-Infective Drug Discovery Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals 3D-QSAR and Docking Studies on Pyrimidine Derivatives as CSF-1R Inhibitors
Letters in Drug Design & Discovery Peptide Phage Display: Opportunities for Development of Personalized Anti-Cancer Strategies
Anti-Cancer Agents in Medicinal Chemistry Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Current Medicinal Chemistry Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Current Pharmaceutical Biotechnology Regulation of Breast Cancer Progression by Noncoding RNAs
Current Cancer Drug Targets Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Post-Stroke Immunodepression and Infection: An Emerging Concept
Infectious Disorders - Drug Targets Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients
Current Medicinal Chemistry Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry